HCW Biologics presented preclinical efficacy for HCW11‑018, a T‑cell engager demonstrating anti‑tumor activity in pancreatic cancer models, while a separate translational study outlined gene‑editing and advanced drug‑delivery strategies to enhance dendritic‑cell‑based immunotherapies. HCW11‑018’s T‑cell engager design targets tumor antigens to redirect T‑cell cytotoxicity toward pancreatic tumor cells—an area with high unmet need due to poor responses to conventional immunotherapy. The dendritic‑cell work focuses on gene‑editing and drug delivery to improve antigen presentation and immune priming in solid tumors. These programs reflect parallel efforts to deploy both bispecific/T‑cell engager platforms and cell‑engineering approaches against immunologically cold tumors. Clinical translation will hinge on safety (on‑target, off‑tumor risk), manufacturability and combination regimens to convert preclinical activity into durable patient responses.